Clinical Trial Update: Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve [Phase 3]

View source ↗

Summary

A Phase III trial of oral thalidomide for advanced hepatocellular carcinoma with poor liver reserve was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Thalidomide (thalidomide)

Snippet

Sponsor: TTY Biopharm | Conditions: Carcinoma, Hepatocellular | Phase 3 | Status: TERMINATED